Vascular Ehlers-Danlos Syndrome Market

DelveInsight’s “Vascular Ehlers-Danlos Syndrome –Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Vascular Ehlers-Danlos Syndrome, historical and forecasted epidemiology as well as the Vascular Ehlers-Danlos Syndrome market trends in the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

The Vascular Ehlers-Danlos Syndrome market report provides current treatment practices, emerging drugs, Vascular Ehlers-Danlos Syndrome market share of the individual therapies, and current and forecasted Vascular Ehlers-Danlos Syndrome market size from 2019 to 2032, segmented by seven major markets. The report also covers current Vascular Ehlers-Danlos Syndrome treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

 

Geography Covered

• The United States
• EU4 (Germany, France, Italy, Spain) and the United Kingdom
• Japan

 

Study period: 2019–2032

Vascular Ehlers-Danlos Syndrome Understanding and Treatment Algorithm

The DelveInsight’s Vascular Ehlers-Danlos Syndrome market report gives a thorough understanding of Vascular Ehlers-Danlos Syndrome by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment. Vascular Ehlers-Danlos syndrome, is a genetic disorder that affects the body’s connective tissue. Connective tissue holds all the body’s cells, organs, and tissue together. It also plays an important role in helping the body grow and develop properly. Connective tissue is made up of proteins. The protein that plays a role in Vascular Ehlers-Danlos Syndrome is called collagen III. Vascular Ehlers-Danlos Syndrome is caused by changes (or mutations) in the gene called COL3A1 that tells the body how to make collagen III. These mutations can result in faulty collagen III throughout the body or a reduction in the amount of normal collagen III in the body (depending on the mutation type). This creates the features and medical problems associated with Vascular Ehlers-Danlos Syndrome. Because collagen III is found throughout the body, Vascular Ehlers-Danlos Syndrome can affect many different parts of the body, including the arteries, hollow organs, skin, and lungs. These systems can be prone to tear, which can be life-threatening.

 

Vascular Ehlers-Danlos Syndrome diagnosis

People with Vascular Ehlers-Danlos Syndrome are born with it, but features of the condition are not always present right away. Some people have signs of Vascular Ehlers-Danlos Syndrome at birth or as young children – including conditions like congenital clubfoot, hip dislocation, limb deformity and visible veins. Bruising may not be an issue when a baby is an infant, but it may become apparent as the child becomes mobile. When a child is seen because of bruising, a potential Vascular Ehlers-Danlos Syndrome diagnosis is not on the radar of the healthcare professionals doing the examination, especially if there is no family history of the condition. The risks of life-threatening events can increase with age. This makes it very important for people with VEDS to receive accurate, early diagnosis and monitoring. Otherwise, the risk for potentially life-threatening complications is greater. The earlier the diagnosis is made, the easier it is to make life-style changes and establish a care plan that can lower the risk of life-threatening complications.

 

Vascular Ehlers-Danlos Syndrome treatment

The key element to the creation of an effective assessment and management plan for people with vascular EDS is a comprehensive knowledge of the natural history of the disorder. The goals of medical management are to minimize the likelihood of adverse events and to assure that quality of life is minimally impaired. The general approach to medical management includes the creation of an informed care team, the avoidance of activity choices that are likely to cause adverse effects, and the management of ordinary medical conditions where there is additional risk in individuals with vascular EDS such that this risk is minimized. The major target of medical intervention has been the maintenance of blood pressure in the normal or low normal range and prevention of surges in blood pressure with the intent to minimize the likelihood of arterial dissection or rupture. Over time, a variety of medications have been suggested that include diuretics, β-adrenergic blockers, angiotensin processing blockers or receptor blockers, and other antihypertensive agents that may depend on knowledge and experience of the clinician.

Vascular Ehlers-Danlos Syndrome Epidemiology

The Vascular Ehlers-Danlos Syndrome epidemiology section provides insights into historical and current Vascular Ehlers-Danlos Syndrome patient pool and forecasted trends for seven individual major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Vascular Ehlers-Danlos Syndrome report also provides the diagnosed patient pool, their trends and assumptions undertaken.

 

Key findings

As per Demmler et al. (2019), the exact number of affected people with Vascular Ehlers-Danlos Syndrome is not known. The best estimates, which combine counts of people who have been identified by genetic testing with calculations of how well that number represents all people, suggest that there are about 1/40,000 – 50,000 people affected with Vascular Ehlers-Danlos Syndrome. Vascular Ehlers-Danlos Syndrome affects both men and women of all races and ethnic groups.

The Vascular Ehlers-Danlos Syndrome epidemiology covered in the report provides historical as well as forecasted Vascular Ehlers-Danlos Syndrome epidemiology [segmented as Total Prevalent Cases of Ehlers-Danlos Syndrome (EDS), Total Diagnosed Prevalent Cases of Ehlers-Danlos Syndrome (EDS), Total Diagnosed Prevalent Cases of Vascular Ehlers-Danlos Syndrome, and Treatable Cases of Vascular Ehlers-Danlos Syndrome] in the 7MM covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan from 2019 to 2032.

 

Country-wise Vascular Ehlers-Danlos Syndrome Epidemiology

The epidemiology segment also provides the Vascular Ehlers-Danlos Syndrome epidemiology data and findings across the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan.

 

Vascular Ehlers-Danlos Syndrome Drug Chapters

The drug chapter segment of the Vascular Ehlers-Danlos Syndrome report encloses the detailed analysis of Vascular Ehlers-Danlos Syndrome marketed drugs and late-stage (Phase III and Phase II) Vascular Ehlers-Danlos Syndrome pipeline drugs. It also helps understand the Vascular Ehlers-Danlos Syndrome clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

Vascular Ehlers-Danlos Syndrome Emerging drugs

The report details the emerging Vascular Ehlers-Danlos Syndrome therapies therapies under the late and mid-stage of development for Vascular Ehlers-Danlos Syndrome treatment

 

EDSIVO: Acer Therapeutics

EDSIVO (celiprolol), is a new chemical entity (NCE), for the treatment of COL3A1+ vEDS patients. In 2015, the US FDA granted EDSIVO (celiprolol) orphan drug designation for the potential treatment of vEDS. In August 2016, the Company signed an agreement with Assistance Publique—Hôpitaux de Paris, Hospital European Georges Pompidou granting the Company the exclusive worldwide rights to access and use data from a randomized, controlled clinical study of celiprolol. The company utilized this clinical data to support an NDA filing for EDSIVO for the treatment of vEDS. Now the company is working towards the goal of approval for EDSIVO.

 

AR101 (enzastaurin): Aytu BioPharma

AR101 (enzastaurin) is a well characterized PKCβ inhibitor for preventing cardiac or arterial events in patients with Vascular Ehlers-Danlos Syndrome confirmed with COL3A1 gene mutations, compared to placebo. Enzastaurin that has been evaluated in over 50 clinical trials, with more than 3300 patients. This includes a Phase III study of nearly 500 patients with 3 years of enzastaurin treatment. The company is yet to start PREVEnt Trial (prevention of rupture with enzastaurin in vascular Ehlers-Danlos syndrome).

 

Note: Detailed emerging therapies assessment will be provided in the full report of stable angina.

Vascular Ehlers-Danlos Syndrome Market Outlook

The Vascular Ehlers-Danlos Syndrome market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Vascular Ehlers-Danlos Syndrome market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

This segment gives a thorough detail of the Vascular Ehlers-Danlos Syndrome market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

Key players such as Acer Therapeutics, and Aytu BioPharma along with few others are involved in developing therapies for stable angina.

According to DelveInsight, the Vascular Ehlers-Danlos Syndrome market in 7MM is expected to witness a major change in the study period 2019–2032.

 

Key findings

This section includes a glimpse of the Vascular Ehlers-Danlos Syndrome market in 7MM.

 

The United States: Vascular Ehlers-Danlos Syndrome Market Outlook

This section provides the total Vascular Ehlers-Danlos Syndrome market size and market size by therapies in the United States.

 

EU4 and the UK: Vascular Ehlers-Danlos Syndrome Market Outlook

The total Vascular Ehlers-Danlos Syndrome market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are provided in this section.

 

Japan: Market Outlook

The total Vascular Ehlers-Danlos Syndrome market size and market size by therapies in Japan is also mentioned.

 

Analyst Commentary

The pipeline of lumbosacral radicular pain is very robust, many potential therapies are being investigated for the treatment of Vascular Ehlers-Danlos Syndrome, and it is safe to predict that the treatment space will experience a significant impact on the market during the forecast period.

The expected introduction of emerging therapies with improved efficacy, more awareness initiatives programs, and further improvement in the diagnosis rate, are likely to boost the growth of the Vascular Ehlers-Danlos Syndrome in the 7MM. Aside from that, the market size of Vascular Ehlers-Danlos Syndrome may flourish due to increased research and development, label-expansion of approved therapies into other epilepsy in this field.

The market growth of Vascular Ehlers-Danlos Syndrome may offset by failures and/or discontinuation of the emerging therapies, unaffordable pricing, market access and reimbursement issues, and a scarcity of healthcare specialists

 

Vascular Ehlers-Danlos Syndrome Drug Uptake

• This section focuses on the rate of uptake of the potential drugs recently launched in the Vascular Ehlers-Danlos Syndrome market or expected to get launched in the market during the study period 2019–2032. The analysis covers Vascular Ehlers-Danlos Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug. 
• This will help in understanding the Vascular Ehlers-Danlos Syndrome drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.
• Vascular Ehlers-Danlos Syndrome Pipeline Development Activities
• The report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Vascular Ehlers-Danlos Syndrome’s key players involved in developing targeted therapeutics.
• Vascular Ehlers-Danlos Syndrome market clinical trial development activities
• The report covers detailed information on collaborations, acquisitions, and mergers, licensing patent details, and other information for Vascular Ehlers-Danlos Syndrome emerging therapies.

 

Vascular Ehlers-Danlos Syndrome Reimbursement Scenario

Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we consider reimbursement to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.

 

KOL Views

To keep up with current epidemiology and market trends, we take KOLs and SMEs' opinions working in the Vascular Ehlers-Danlos Syndrome domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies and treatment patterns along with Vascular Ehlers-Danlos Syndrome market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

 

Competitive Intelligence Analysis

We perform competitive and market intelligence analysis of the Vascular Ehlers-Danlos Syndrome market by using various competitive intelligence tools that include – SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

 

Scope of the Report

• Descriptive overview of Vascular Ehlers-Danlos Syndrome, disease overview, patient journeys, treatment algorithms, diagnosis, and currently available therapies
• Comprehensive insight into the Vascular Ehlers-Danlos Syndrome epidemiology and forecasts in the 7MM
• An all-inclusive account of both the current and emerging therapies for Vascular Ehlers-Danlos Syndrome, along with the assessment of new therapies, expected to have an impact on the current treatment landscape
• Exhaustive analysis of the Vascular Ehlers-Danlos Syndrome market; historical and forecasted covering drug outreach in the 7MM
• Trends shaping and driving the global Vascular Ehlers-Danlos Syndrome market

 

Report Highlights

• In the coming years, the Vascular Ehlers-Danlos Syndrome market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
• The companies and academics are working to assess challenges and seek opportunities that could influence Vascular Ehlers-Danlos Syndrome R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition  
• Major players are involved in developing Vascular Ehlers-Danlos Syndrome therapies. The launch of emerging therapies will significantly impact the Vascular Ehlers-Danlos Syndrome market
• A better understanding of Vascular Ehlers-Danlos Syndrome pathogenesis will also contribute to the development of novel therapeutics for Vascular Ehlers-Danlos Syndrome
• Our in-depth analysis of the Vascular Ehlers-Danlos Syndrome pipeline assets across different stages of development (Phase III and Phase II), emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

 

Vascular Ehlers-Danlos Syndrome Report Insights

• Patient population
• Therapeutic approaches
• Vascular Ehlers-Danlos Syndrome pipeline analysis
• Vascular Ehlers-Danlos Syndrome market size and trends
• Vascular Ehlers-Danlos Syndrome market opportunities
• Impact of upcoming therapies

 

Vascular Ehlers-Danlos Syndrome Report Key Strengths

• 11 years forecast
• 7MM coverage
• Vascular Ehlers-Danlos Syndrome epidemiology segmentation
• Key cross competition
• KOL views
• Vascular Ehlers-Danlos Syndrome drugs uptake

 

Vascular Ehlers-Danlos Syndrome Report Assessment

• Current treatment practices
• Unmet needs
• Vascular Ehlers-Danlos Syndrome pipeline product profiles
• Vascular Ehlers-Danlos Syndrome market attractiveness

 

Key Questions

 

Vascular Ehlers-Danlos Syndrome Market Insights:

• What would be the Vascular Ehlers-Danlos Syndrome market growth till 2032, and what will be the resultant market size in 2032?
•  What was the Vascular Ehlers-Danlos Syndrome drug class share (in percentage) distribution in 2019, and how would it look in 2032?
• What would be the Vascular Ehlers-Danlos Syndrome total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
• What are the key findings of the market across 7MM, and which country will have the largest Vascular Ehlers-Danlos Syndrome market size during the forecast period (2019–2032)
• How would the unmet needs affect the Vascular Ehlers-Danlos Syndrome market dynamics and subsequent analysis of the associated trends?

 

Vascular Ehlers-Danlos Syndrome Epidemiology Insights:

• What are the disease risk, burden, and regional/ethnic differences of Vascular Ehlers-Danlos Syndrome?
• What is the historical and forecasted Vascular Ehlers-Danlos Syndrome patient pool in 7MM, and where can one observe the highest patient population and growth opportunities?
• What are the key factors driving the epidemiology trends for seven major markets covering the United States, EU4 (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• ent Treatment Scenario, Marketed Drugs, and Emerging Therapies
• What are the current treatment guidelines and treatment options, in addition to approved therapies for Vascular Ehlers-Danlos Syndrome in the US, Europe, and Japan?
• What are the key collaborations (Industry–Industry, Industry-Academia), mergers and acquisitions, and licensing activities related to Vascular Ehlers-Danlos Syndrome therapies?
• What are the recent novel therapies, targets, mechanisms of action, and technologies being developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Vascular Ehlers-Danlos Syndrome and its status, along with the challenges faced?

 

Reasons to Buy

• The report will help in developing business strategies by understanding trends shaping and driving the Vascular Ehlers-Danlos Syndrome market
• Organize sales and marketing efforts by identifying the best opportunities for Vascular Ehlers-Danlos Syndrome in the US, Europe (Germany, Spain, Italy, France, and the UK), and Japan
• Identification of strong upcoming players in the market that will help devise strategies that will help in getting ahead of competitors